SEC 13F Intelligence

Birchview Capital, LP / ACAD

Birchview Capital, LP’s Acadia Pharmaceuticals Inc Position

Does Birchview Capital, LP own Acadia Pharmaceuticals Inc (ACAD)? Yes171.0K shares worth $4M (+2.17% of its 13F portfolio) as of Q1 2026.

Position Value
$4M
Q1 2026
Shares
171.0K
% of Portfolio
+2.17%
Quarters Held
28
currently held

Position History ACAD

Reported value by quarter
Q2 ’19: $267,000Q2 ’19Q3 ’19: $504,000Q4 ’19: $599,000Q1 ’20: $4MQ2 ’20: $5MQ2 ’20Q3 ’20: $4MQ4 ’20: $5MQ1 ’21: $5MQ2 ’21: $5MQ2 ’21Q3 ’21: $3MQ4 ’21: $5MQ1 ’22: $5MQ2 ’22: $4MQ2 ’22Q3 ’22: $4MQ4 ’22: $3,970Q1 ’23: $4,694Q2 ’23: $6MQ2 ’23Q3 ’23: $5MQ4 ’23: $8MQ1 ’24: $5MQ2 ’24: $4MQ2 ’24Q3 ’24: $6MQ4 ’24: $6MQ1 ’25: $4MQ2 ’25: $4MQ2 ’25Q3 ’25: $4MQ4 ’25: $5MQ1 ’26: $4Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 2026171.0K$4M+2.17%
Q4 2025171.0K$5M+2.67%
Q3 2025171.0K$4M+2.76%
Q2 2025187.8K$4M+4.02%
Q1 2025263.4K$4M+3.80%
Q4 2024338.4K$6M+5.06%
Q3 2024400.4K$6M+5.34%
Q2 2024250.4K$4M+3.77%
Q1 2024250.4K$5M+3.78%
Q4 2023240.4K$8M+5.90%
Q3 2023240.4K$5M+4.26%
Q2 2023249.4K$6M+4.48%
Q1 2023249.4K$4,694+3.68%
Q4 2022249.4K$3,970+2.80%
Q3 2022249.4K$4M+2.87%
Q2 2022249.4K$4M+2.56%
Q1 2022199.4K$5M+3.48%
Q4 2021199.4K$5M+3.00%
Q3 2021199.4K$3M+2.25%
Q2 2021199.4K$5M+2.91%
Q1 2021177.0K$5M+2.71%
Q4 2020102.0K$5M+3.14%
Q3 2020102.0K$4M+2.81%
Q2 202093.0K$5M+2.72%
Q1 202092.0K$4M+3.45%
Q4 201914.0K$599,000+0.44%
Q3 201914.0K$504,000+0.34%
Q2 201910.0K$267,000+0.16%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Birchview Capital, LP’s full portfolio or all institutional holders of ACAD.